Laurus Labs Limited (LAURUSLABS) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Laurus Labs Limited ₹353, price ₹2,034, upside -82.6%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Stretched ValuationStrong overvaluation with only moderate quality.
!Fair value ₹353.43 · Strongly overvalued (−83%)
!Quality 60/100
!Mixed Growth(revenue 5y +7.2 %/yr)
✓Solidly profitable · 13.1% net margin (TTM)
✓Low debt · generates free cash flow
·0.08% dividend yield
!Mixed vs. peers(6/14)
!Moderate moat64/100
!Insider activity40/100
!Evidence only low, so the estimate is less certain
Watch Laurus Labs Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹286.97 – ₹2,034 · fair‑value band ₹176.49 – ₹452.42 · the ₹2,034 price screens above the ₹353.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 24, 2026.
Follow Laurus Labs in your weekly email
Every Wednesday you see whether Laurus Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally.
Show more
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Stock analysis
Laurus Labs Limited (LAURUSLABS) currently trades at ₹2,034, while our model-based Fair Value estimate is ₹353.43, implying the stock looks roughly 475.4% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹376.66 per share, and 0 of the 26 models we run sit above the ₹2,034 price.
Bear case: the Asset-Based group reads lowest at ₹65.73, and 26 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹176.49 (bear) to ₹452.42 (bull), the price of ₹2,034 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Laurus Labs Limited reported revenue of ₹68.1B in FY2026 versus ₹49.4B in FY2022, a compound +8.4%/yr. Reported net income was ₹8.9B in FY2026, compounding +1.8%/yr from FY2022.
Key figures
Market cap ₹1.1T (≈ $11.4B) · P/E ratio 130.1 · P/S ratio 17.0 · EPS (TTM) ₹15.63 · Dividend yield 0.1% · Net margin 13.0% · Return on equity 17.7% · Return on assets (EBIT) 24.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 145% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −83%, LAURUSLABS screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹27.49 to ₹599.36). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹176.49Fair Value ₹353.43Bull ₹452.42
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹7.20 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.70/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Start year 2021 (pandemic). Over 10 years: +14.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−10.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−10.5%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1% vs 20%, slowing
Profit margin 2013 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 19%
2026 sits 148% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+65.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +58.8% a year for the price and +9.1% for the forecasts.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 612 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside−83% · Bottom 25%
Profitability
Return on equity (TTM)18% · Top 25%
Return on assets8% · Top 25%
Net margin (TTM)13% · Above median
Operating margin (TTM)22% · Top 25%
Growth and dividend
Revenue growth5% · Above median
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (TTM)130.1× · Priciest 25%
P/B20.73× · Priciest 25%
P/S (TTM)16.13× · Priciest 25%
P/FCF2.9× · Pricier than median
EV/EBITDA62.0× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 12
FUTURE (revenue growth)27· sector 21
PAST (return on equity)71· sector 25
HEALTH (low debt)94· sector 96
DIVIDEND (yield)2· sector 30
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Laurus Labs Limited (LAURUSLABS) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹353.43 versus a price of ₹2,034, about −83% upside (overvalued).
What is the fair value of LAURUSLABS?
Our model-based fair value for Laurus Labs Limited is ₹353.43 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹2,034.
What is the quality score of LAURUSLABS?
Laurus Labs Limited has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Laurus Labs Limited (LAURUSLABS)?
Our model-based price target is the fair value of ₹353.43 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹176.49, optimistic scenario ₹452.42. It is a calculation from audited fundamentals, not an analyst target.
What is the Laurus Labs Limited stock forecast for 2026?
Our models put fair value at ₹353.43, about −83% upside versus a price of ₹2,034 (overvalued). Cautious scenario ₹176.49, optimistic scenario ₹452.42. The calculation is refreshed regularly with new filings.
What is the revenue of Laurus Labs Limited (LAURUSLABS)?
Laurus Labs Limited reported trailing-twelve-month revenue of about ₹68.1B (latest available figure, as of Sep 24, 2026).
Does Laurus Labs Limited pay a dividend?
Laurus Labs Limited currently shows a dividend yield of about 0.08% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Laurus Labs Limited (LAURUSLABS)?
For today's price to be fair in a discounted-cash-flow model, Laurus Labs Limited would have to grow free cash flow by +65.3 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of LAURUSLABS use?
Our models discount Laurus Labs Limited at 9.9 %: a base by market capitalisation (mega), damped by beta 0.43, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Laurus Labs Limited that is +65.3 % per year a year over ten years, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has Laurus Labs Limited (LAURUSLABS) delivered so far?
Over the past 5 years revenue at Laurus Labs Limited grew +7.2 % a year. The price currently implies +65.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Laurus Labs Limited (LAURUSLABS) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Laurus Labs Limited (+65.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Laurus Labs Limited (LAURUSLABS)?
The free-cash-flow yield on the price is 0.35 %: that much free cash flow Laurus Labs Limited produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Laurus Labs Limited (LAURUSLABS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Laurus Labs Limited it is ₹353.43 per share (as of Sep 24, 2026), against a price of ₹2,034. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Laurus Labs Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, LAURUSLABS trades above its calculated fair value: price ₹2,034, fair value ₹353.43, a gap of about −83% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LAURUSLABS?
No. The price is what the market pays today (₹2,034); the fair value is what the company's own numbers justify (₹353.43). For Laurus Labs Limited the two are ₹1,681 per share apart. That gap is exactly why we show both numbers side by side.
How much is Laurus Labs Limited worth?
The market values Laurus Labs Limited at about ₹1.1T (market capitalisation, as of Sep 24, 2026). Per share that is ₹2,034; our models calculate a fair value of ₹353.43 per share.
What do the bullish and bearish scenarios say about LAURUSLABS?
Our models span a range for Laurus Labs Limited: cautious scenario ₹176.49, base ₹353.43, optimistic ₹452.42 per share (as of Sep 24, 2026, price ₹2,034). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LAURUSLABS?
Laurus Labs Limited trades at a price-to-earnings ratio of 130.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹353.43 is built from several models across several years. Other multiples: P/B 20.7, P/S 16.1, EV/EBITDA 62.0.
How solid is the balance sheet of Laurus Labs Limited (LAURUSLABS)?
Balance-sheet figures for Laurus Labs Limited (as of Sep 24, 2026): return on equity 17.7%, debt of 0.12 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is LAURUSLABS from its 52-week high?
Laurus Labs Limited trades at ₹2,034, at its 52-week high of ₹2,034 and 145% above the low of ₹830.79 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ₹353.43 is for.
Which stocks are comparable to Laurus Labs Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Laurus Labs Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹2,034, calculated fair value ₹353.43 (−83%), Quality Score 60/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LAURUSLABS calculated?
We run Laurus Labs Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹353.43, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Laurus Labs Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Laurus Labs Limited (LAURUSLABS)?
The closing price on Sep 23, 2026 was ₹2,034. Our model-based fair value is ₹353.43, about −83% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Laurus Labs Limited right now?
The price sits above even our optimistic bull case (₹452.42). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹176.49 to ₹452.42) leaves room in how you read the outcome.
Where does the earnings growth of Laurus Labs Limited (LAURUSLABS) come from?
Earnings per share at Laurus Labs Limited grew +13.3 % a year from 2015 to 2026. Broken into its drivers: revenue per share +12.9 %, EBIT margin +1.2 %, tax rate −1.3 %, residual (interest, one-offs) +0.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Laurus Labs Limited
How large is the market capitalisation of Laurus Labs Limited (LAURUSLABS)?
The market capitalisation of Laurus Labs Limited is ₹1.1T (≈ $11.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Laurus Labs Limited (LAURUSLABS)?
The price-to-sales ratio of Laurus Labs Limited is 17.0 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Laurus Labs Limited (LAURUSLABS)?
Earnings per share at Laurus Labs Limited are ₹15.63 (price ÷ EPS = P/E 130.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Laurus Labs Limited (LAURUSLABS)?
The dividend yield of Laurus Labs Limited is 0.1% (payout 10.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Laurus Labs Limited (LAURUSLABS)?
The net margin of Laurus Labs Limited is 13.0% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Laurus Labs Limited (LAURUSLABS)?
The return on equity (ROE) of Laurus Labs Limited is 17.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Laurus Labs Limited (LAURUSLABS)?
On an EBIT basis the return on assets of Laurus Labs Limited is 24.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Laurus Labs Limited (LAURUSLABS)?
The operating margin of Laurus Labs Limited is 21.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Laurus Labs Limited (LAURUSLABS)?
Revenue at Laurus Labs Limited is growing +5.3% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Laurus Labs Limited (LAURUSLABS)?
Earnings per share at Laurus Labs Limited are growing +19.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Laurus Labs Limited (LAURUSLABS) carry?
The net debt of Laurus Labs Limited is ₹24.0B (fiscal year 2026, ≈ 6.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Laurus Labs Limited in the live analysis
One click puts Laurus Labs Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
